- Home
- NBXG vs COLL Comparison
NBXG vs COLL Comparison
Compare NBXG & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBXG | COLL |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NBXG | COLL |
|---|---|---|
| Price | $15.15 | $35.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $51.40 |
| AVG Volume (30 Days) | 240.5K | ★ 337.0K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $88.48 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $12.32 | $29.70 |
| 52 Week High | $17.43 | $50.79 |
Technical Indicators
Market Signals| Indicator | NBXG | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 46.95 |
| Support Level | $14.81 | $33.93 |
| Resistance Level | $15.70 | $35.76 |
| Average True Range (ATR) | 0.41 | 1.40 |
| MACD | -0.04 | -0.10 |
| Stochastic Oscillator | 56.30 | 28.38 |
Price Performance
Historical ComparisonAbout NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in NextGen Companies.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.